
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
New Data at AACR Showcase Reaction Biology's Innovative Approach to Oncology Drug Discovery Services
Details : Adavosertib (AZD1775, MK-1775), a clinical-stage inhibitor of tyrosine kinase WEE1, exhibited a broad anti-cancer activity across all hematological and solid tumor types with IC50 values ranging from 0.06 to 10 µM, matching consistently high expression...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2022
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
